Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Aktis Oncology, Inc.NASDAQ: AKTS
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings of -$174.89M in Q1 FY2026
Q1 FY2026 retained earnings was -$174.89M.
Context
- Retained earnings amounted to 30.3% of total assets at the end of Q1 FY2026.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (156.56M) USD
- Year-over-year change
- -68.7%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (156.56M) | -68.7% |
| FY2024 | 2024-12-31 | (92.83M) | -90.0% |
| FY2023 | 2023-12-31 | (48.85M) | -141.7% |
| FY2022 | 2022-12-31 | (20.21M) | — |
Retained Earnings vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 retained earnings of -$174.89M is the highest of the 6 companies compared; the peer median is -$940.91M.
- Retained earnings amounts to 30.3% of total assets for AKTS, versus a peer median of 186.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$174.89M | — | — | 30.3% | |
| Mar 2026 | -$514.1M | -28.0% | — | 373.4% | |
| Mar 2026 | -$818.3M | -3.5% | — | 76.3% | |
| Sep 2026 | -$940.91M | -42.9% | — | 186.1% | |
| Mar 2026 | -$960.58M | -29.5% | — | 147.2% | |
| Mar 2026 | -$1.28B | -5.8% | — | 588.0% | |
| Peer median (excluding AKTS) | -$940.91M | -28.0% | — | 186.1% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.